Xenon Pharmaceuticals Inc. — Q2 2019 Form 10-Q
Business context and period. Clinical-stage biopharmaceutical company focused on neurology, particularly epilepsy. This unaudited report covers the quarter and six months ended June 30, 2019; amounts below are in U.S. dollars unless stated otherwise. Xenon had no significant product revenue and reported no collaboration revenue in the periods presented.
Financial performance and liquidity
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $8.2 million | $5.4 million | $17.3 million | $11.0 million |
| General and administrative expense | $2.3 million | $2.2 million | $4.9 million | $4.4 million |
| Total operating expense / operating loss | $10.5 million | $7.6 million | $22.3 million | $15.4 million |
| Net loss | $10.0 million | $7.8 million | $21.3 million | $11.6 million |
| Net loss per common share | $0.37 | $0.45 | $0.80 | $0.66 |
| Cash used in operating activities | Not separately provided | Not separately provided | $17.3 million | $13.8 million |
At June 30, 2019, cash and cash equivalents were $37.1 million and marketable securities were $64.7 million, totaling $101.8 million. Total assets were $105.9 million; total liabilities were $23.1 million. The term loan had $15.5 million principal outstanding and a 9.53% effective interest rate; $2.1 million was classified as current and $13.2 million as long-term on the balance sheet. The company reported compliance with loan covenants.
Margins are not meaningful because the company reported no revenue. Shareholders’ equity was $82.8 million, down from $103.3 million at year-end 2018. Accumulated deficit was $229.4 million. Six-month investing cash outflow of $13.8 million primarily reflected net purchases of marketable securities; financing cash inflow was $0.1 million.
Material changes versus comparable periods
- Q2 operating expenses increased $2.9 million year over year, primarily from higher spending on XEN1101 and XEN496 and increased discovery and preclinical costs. Six-month R&D expense rose $6.4 million, reflecting higher spending across XEN496, XEN901 and XEN1101.
- Six-month net loss increased to $21.3 million from $11.6 million. The 2018 comparison included a one-time $4.4 million gain on termination of the Teva collaboration; excluding that item, the year-over-year loss increase was still substantial.
- Six-month operating cash use rose $3.5 million. Cash and cash equivalents declined by $30.7 million from year-end, while marketable securities increased by $13.2 million.
- Weighted-average common shares for Q2 rose to 25.8 million from 14.3 million in 2018, reflecting prior equity issuance. Common-share loss per share was lower in Q2 2019 despite a larger net loss, partly reflecting the larger share base and allocation of losses between common and preferred shareholders.
Outlook, programs and risks
- Management expects significant expenses and operating losses for the foreseeable future, including at least the next 12–24 months. It stated that cash, cash equivalents and marketable securities were expected to fund operating and capital needs for at least 12 months, while cautioning that assumptions could prove incorrect. The company expects to need further collaboration, equity or debt financing to advance development and potential commercialization.
- XEN1101: Phase 2b trial in about 300 adults with focal epilepsy was underway, with site selection and enrollment in the U.S., Canada and Europe. Top-line results were anticipated in the second half of 2020, depending on enrollment.
- XEN496: pediatric-specific ezogabine formulation; a healthy-volunteer pharmacokinetic study was expected to begin in Q3 2019, with an IND filing expected in Q4 2019 to support a planned KCNQ2-DEE trial.
- XEN901: pediatric formulation development was completed; juvenile toxicology work was underway. A healthy-volunteer pharmacokinetic study was intended to begin in Q3 2019, followed by an IND submission for a proposed SCN8A-EE trial.
- XEN007: a physician-led open-label Phase 2 study in childhood absence epilepsy was anticipated in the near term; other development strategies remained under consideration.
- Key risks include clinical, regulatory, safety and enrollment uncertainty; formulation and manufacturing challenges; dependence on collaborators, CROs and contract manufacturers; limited patent protection for certain candidates; foreign-exchange exposure; and the need for additional capital. Financing could dilute shareholders or require concessions over product rights.
- Potential obligations include development and regulatory milestones and royalties under license arrangements. The filing reports no material legal proceedings expected by management to have an adverse effect. No material change in previously disclosed contractual commitments was reported.
- The company adopted ASC 842 lease accounting in January 2019, recognizing a right-of-use asset and lease liabilities; it reported no material effect on operations or cash flows. Management stated disclosure controls were effective at a reasonable-assurance level and that there were no material changes in internal control over financial reporting.
Investor verification priorities
- Confirm actual progress against the stated XEN496 and XEN901 study and IND timelines, and XEN1101 enrollment and data timing.
- Track quarterly operating cash use, liquidity composition and runway assumptions; marketable securities are not the same as cash balances.
- Review financing needs, loan repayment schedule, 9.53% effective borrowing cost, covenants and any potential dilution from equity or convertible securities.
- Assess clinical results, safety, recruitment feasibility and regulatory requirements for the company’s rare-disease programs.
- Review possible milestone, royalty and other contingent payments under licensing and acquisition agreements, including obligations tied to XEN1101 and XEN007.